Lung Cancer Therapy Market Scope And Analysis

Report Code : TIPRE00030093
Category : Medical Device

Status : Published
No. of Pages : 206

Buy Now

Lung Cancer Therapy Market Scope and Key Players Analysis by 2030

Buy Now

Lung Cancer Therapy Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 31.02 Billion
Market Size by 2030	US$ 80.49 Billion
Global CAGR (2022 - 2030)	12.7%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Therapy Type Noninvasive and Minimally Invasive By Indication Non-Small Cell Lung Cancer and Small Cell Lung Cancer By End User Hospitals Oncology Clinics Research Centers
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Medtronic PLC RF Medical Co Ltd Johnson Johnson Merck KGaA Sun Pharmaceutical Industries Ltd Bioventus Inc Meiji Seika Pharma Co Ltd Advanz Pharma Corp Olympus Corp

Industry Developments and Future Opportunities:

Various initiatives by key players operating in the Lung Cancer Therapy Market are listed below:

In October 2023, Johnson & Johnson submitted the Type II extension of indication application seeking approval of the European Medicines Agency (EMA) for the use of RYBREVANT (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed) as the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
In December 2022, RF Medical Co Ltd announced that the FDA approved their patented MYGEN M-3004 generator and MYOBLATE radiofrequency ablation system for commercialization in the US. These devices are used to treat damaged tumors and tissues.
May 2021, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The drug is indicated among patients showing disease progression on or after platinum-based chemotherapy. RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.

Competitive Landscape and Key Companies:

A few of the prominent players operating in the lung cancer therapy market are Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp. These companies focus on new product launches and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.